Fannie Mae, Freddie Mac shares tumble after conservatorship comments
DEERFIELD, Ill. - Baxter International Inc. (NYSE:BAX) reported first-quarter earnings that exceeded analyst expectations and raised its full-year outlook, sending shares up 2.6% in early trading Thursday.
The global medtech company posted adjusted earnings per share of $0.55 for Q1, surpassing the analyst consensus of $0.48. Revenue came in at $2.63 billion, above estimates of $2.59 billion and up 5% YoY on both a reported and operational basis.
Baxter’s solid performance was driven by better-than-expected sales in its Medical (TASE:BLWV) Products & Therapies and Healthcare Systems & Technologies segments. U.S. sales rose 11% to $1.49 billion, while international sales increased 3% operationally to $1.14 billion.
"Our solid performance in the first quarter of 2025 reflects the ongoing impact of our transformation journey," said Brent Shafer, chair and interim CEO. "Baxter today is a more focused and agile organization, well positioned to drive enhanced value for patients, healthcare providers, customers and shareholders."
For the second quarter, Baxter expects adjusted EPS of $0.59 to $0.63 on sales growth of 4% to 5%. The company raised the low end of its full-year 2025 adjusted EPS guidance to $2.47-$2.55, compared to the previous range of $2.45-$2.55.
The Medical Products & Therapies segment saw 6% operational growth, driven by strong demand for IV infusion pumps and nutrition therapies in the U.S. Healthcare Systems & Technologies sales rose 6%, fueled by robust U.S. sales of Patient Support Systems products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.